Salvinorin B (SALB)

(HB4887)

Product overview

  • Name
    Salvinorin B (SALB)
  • Short description
    Potent, selective KORD DREADD activator
  • Biological description

    Salvinorin B (SALB) is a pharmacologically inert ligand that potently and selectively activates the KORD (the κ-opioid designer receptor (DREADD)) (EC50 = 11.8 nM).


    Salvinorin B (SALB) is ~100-fold selective for the KORD DREADD over human κ opioid receptor and other targets and shows good CNS penetrability.


    Activation of KORD by Salvinorin B (SALB) induces neuronal inhibition and modifies behaviour in vivo.


    Salvinorin B (SALB) can be used in mice also expressing Clozapine N-Oxide (CNO) responsive DREADDS, to allow bi-directional manipulation of neural circuits.


    Clozapine N-Oxide (CNO) also available.

  • Alternative names
    SALB, Divinorin B
  • Biological action
    Activator
  • Purity
    >98%
  • Citations

Properties

  • Chemical name
    (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(3-Furanyl)dodecahydro-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-2H-naphtho[2,1-c]pyran-7-carboxylic acid methyl ester
  • Molecular Weight
    390.43
  • Chemical structure
    Salvinorin B | [92545-30-7]
  • Molecular Formula
    C21H26O7
  • CAS Number
    92545-30-7
  • PubChem identifier
    11440685
  • SMILES
    C[C@@]12CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]1C(=O)[C@H](C[C@H]2C(=O)OC)O)C)C4=COC=C4
  • Source
    Extracted from salvia divinorum
  • InChi
    InChI=1S/C21H26O7/c1-20-6-4-12-19(25)28-15(11-5-7-27-10-11)9-21(12,2)17(20)16(23)14(22)8-13(20)18(24)26-3/h5,7,10,12-15,17,22H,4,6,8-9H2,1-3H3/t12-,13-,14-,15-,17-,20-,21-/m0/s1
  • InChiKey
    BLTMVAIOAAGYAR-CEFSSPBYSA-N
  • MDL number
    MFCD16036232
  • Appearance
    Off-white solid

Storing and Using Your Product

  • Storage instructions
    -20 °C
  • Solubility overview
    Soluble in DMSO (20 mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for Salvinorin B (SALB)

  • A New DREADD Facilitates the Multiplexed Chemogenetic Interrogation of Behavior.

    Vardy et al (2015) Neuron. 86(4) : 936-46.
    PubMedID: 25937170
  • DREADDS: Use and application in behavioral neuroscience.

    Smith et al (206) Behav Neurosci 130(2) : 137-55.
    PubMedID: 26913540
  • Behavioral and Physiological Effects of a Novel Kappa-Opioid Receptor-Based DREADD in Rats.

    Marchant et al (2016) Neuropsychopharmacology 41(2) : 402-9.
    PubMedID: 26019014
  • Antinociceptive and hypothermic effects of Salvinorin A are abolished in a novel strain of kappa-opioid receptor-1 knockout mice.

    Ansonoff MA et al (2006) J Pharmacol Exp Ther 318 (2): : 641-8.
    PubMedID: 16672569